No Data
No Data
INKON Life Technology: Half-year report for the year 2024.
INKON Life Technology: Summary of Half-Year Report in 2024.
Inkon life technology (300143.SZ): net income in the first half of the year was 54.8011 million yuan, a year-on-year decrease of 22.44%
In August 22th, 2024, Inkon Life Technology (300143.SZ) announced its semi-annual report for the year, with revenue of 0.823 billion yuan, a year-on-year increase of 13.74%; net income attributable to shareholders of the listed company of 54.8011 million yuan, a year-on-year decrease of 22.44%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 50.8226 million yuan, a year-on-year decrease of 24.34%; basic earnings per share of 0.0860 yuan.
Inkon Life Technology (300143.SZ): The shareholding period of the controlling shareholder has passed halfway, with a cumulative increase of 5.6334 million shares.
On July 29th, Gelunhui reported that Inkon Life Technology (300143.SZ) announced that the shareholding plan of its controlling shareholder, Inkon Medical Investment, has passed its implementation period as of July 29th, 2024. Since the date of the plan's announcement until July 29th, 2024, Inkon Medical Investment has cumulatively increased its shareholding in the company by 5.6334 million shares, accounting for 0.89% of the company's current total share capital, and the increase amount is 44.6737 million yuan through the concentrated bidding trading system of the Shenzhen Stock Exchange. The shareholding plan has not yet been completed, and Inkon Medical Investment will continue to increase its shareholding in the company in accordance with the plan.
Inkon Life Technology (300143.SZ): As of July 19th, the total number of shareholders of the company is 16,124.
Inkron Life Technology (300143.SZ) stated on the investor interaction platform on July 22nd that as of July 19, 2024, the total number of shareholders of the company was 16,124.
Inkon Life Technology (300143.SZ): With the introduction of AI-assisted diagnostic system, the clinical detection rate of pulmonary nodules has increased by 32%.
In its investor relations event on July 17th, Inkon Life Technology (300143.SZ) stated that it will further enhance user experience through digitalization. Taking Suzhou Guangci Cancer Hospital as an example, the hospital continues to explore and actively deploy AI applications. In terms of doctor experience, the clinical detection rate of pulmonary nodules increased by 32% and doctors' film reading efficiency improved by 26% through the introduction of an AI-assisted diagnostic system. By reconstructing the patient's image data into a 3D model, doctors can rotate the 3D image from all angles, simulate the surgical procedures before surgery, and plan the optimal surgical path. The application of AI has improved the efficiency and accuracy of diagnosis and treatment. Patient experience improved as well.
No Data